Related Experiment Video
Updated: May 10, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
Taylor J Brueseke1, Krishnansu S Tewari
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, CA, USA.
Abstract:
Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer.
Insights
New research explores VTX-2337, a Toll-like receptor 8 activator, for treating ovarian cancer by targeting its immunosuppressive microenvironment. This approach aims to enhance innate immunity and overcome treatment resistance in recurrent cases.
Area of Science:
- Gynecologic Oncology
- Immunology
- Pharmacology
Background:
- Ovarian cancer is a leading cause of cancer death among gynecologic malignancies.
- Ovarian tumors possess an immunosuppressive microenvironment that hinders effective treatment.
- Activating the innate immune response presents a potential strategy to reverse tumor-induced immunosuppression.
Purpose of the Study:
- To evaluate the efficacy of VTX-2337, a novel Toll-like receptor 8 (TLR8) agonist, in patients with recurrent platinum-resistant ovarian cancer.
- To investigate the potential of TLR8 activation to modulate the tumor microenvironment and overcome immunosuppression.
- To assess VTX-2337 within the context of a Phase II clinical trial for ovarian cancer treatment.
Main Methods:
- A Phase II, randomized, double-blind, placebo-controlled trial (GOG-3003) was conducted.
- VTX-2337, a small molecule TLR8 ligand, was administered to patients with recurrent platinum-resistant ovarian cancer.
- The study involved comparing VTX-2337 treatment against a placebo.
Main Results:
- The study is ongoing, and results are pending.
- The trial aims to provide data on the safety and efficacy of VTX-2337.
- Anticipated outcomes will inform the role of TLR8 agonists in ovarian cancer therapy.
Conclusions:
- VTX-2337 represents a promising therapeutic candidate targeting the immunosuppressive tumor microenvironment in ovarian cancer.
- Activation of Toll-like receptor 8 may offer a novel treatment strategy for recurrent platinum-resistant ovarian cancer.
- The ongoing clinical trial results are crucial for validating the potential of process therapy in ovarian cancer treatment.
